Valacyclovir versus acyclovir for HSV prophylaxis in neutropenic patients

Annals of Pharmacotherapy

Volumn 36, Issue 10, 2002, Pages 1525-1531

  Warkentin, Dawn I ^a   Epstein, Joel B ^a   Campbell, Lara M ^a   Yip, Judy G ^a   Cox, Victoria C ^a   Ransier, Allison ^a   Barnett, Michael J ^a   Marra, Fawziah ^a   Suárez, Encarnación C ^a   Longtin, Jean ^a  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

Acyclovir; Stem cell transplantation; Valacyclovir

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; VALACICLOVIR;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; LIVER TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELODYSPLASIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; SKIN TOXICITY; SOMNOLENCE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; VIRUS REACTIVATION; VIRUS SHEDDING;

EID: 0036785182     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A434     Document Type: Article

References (31)

1. Koc Y, Miller KB, Schenkein DP, Griffith J, Akhtar M, DesJardin J, et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000;6:44-9.
2. Boeckh M, Gooley TA, Bowden RA. Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia. J Infect Dis 1998;178:1153-7.
3. Rieux C, Gautheret-Dejean A, Challine-Lehmann D, Kirch C, Agut H, Vernant JP. Human herpesvirus-6 meningoencephalitis in a recipient of an unrelated allogeneic bone marrow transplant. Transplantation 1998; 65:1408-11.
4. Tanaka-Taya K, Okada S. [Human herpesvirus-6 and -7 infection and bone marrow transplantation (BMT)]. Japanese. Nippon Rinsho 1998;56: 208-12.
5. Mookerjee BP, Vogelsang G. Human herpes virus-6 encephalitis after bone marrow transplantation: successful treatment with ganciclovir. Bone Marrow Transplant 1997;20:905- 6.
6. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981;305:63-7.
7. Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis 1994;18:273-84.
8. Epstein JB, Ransier A, Sherlock CH, Spinelli JJ, Reece D. Acyclovir prophylaxis of oral herpes virus during bone marrow transplantation. Eur J Cancer B Oral Oncol 1996;32B:158-62.
9. Ljungman P, Wilczek H, Gahrton G, Gustavsson A, Lundgren G, Lonnqvist B, et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant 1986;1:185-92.
10. Bergmann OJ, Ellermann-Eriksen S, Mogensen SC, Ellegaard J. Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomized, double blind, placebo controlled trial. BMJ 1995;310:1169-72.
11. Shepp DH, Dandliker PS, Flournoy N, Meyers JD. Sequential intravenous and twice daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients. Transplantation 1987;43:654-8.
12. Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 1984;100:823-8.
13. Hann IM, Prentice HG, Blacklock HA, Ross MG, Brigden D, Rosling AE, et al. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomized double blind trial. BMJ 1983;287:384-8.
14. Gluckman E, Lotsberg J, Devergie A, Zhao XM, Melo R, Gomez-Morales M, et al. Prophylaxis of herpes infections after bone marrow transplantation by oral acyclovir. Lancet 1983;2:706-8.
15. Wagstaff AJ, Faulds D, Goa KL. Aciclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994;47:153-205.
16. Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605.
17. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995;39:2759-64.
18. Acosta EP, Fletcher CV. Valacyclovir. Ann Pharmacother 1997;31:185-91.
19. Hasenburg A, Tong XW, Rojas-Martinez A, Nyberg-Hoffman C, Kieback CC, Kaplan AL, et al. Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilitates outpatient treatment. Anticancer Res 1999;19:2163-5.
20. Reitano M, Tyring S, Lang W, Thoming C, Worm AM, Borelli S, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998;178: 603-10.
21. Fife KH, Barbarash RA, Rudolph T, Degregorio B, Roth R. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. Sex Transm Dis 1997;24:481-6.
22. Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K. A largescale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch Intern Med 1996; 156:1729-35.
23. Tyring SK, Douglas JM Jr, Corey L, Spruance SL, Esmann J. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch Dermatol 1998;134:185-91.
24. Patel R, Bodsworth NJ, Woolley P, Peters B, Vejlsgaard G, Saari S, et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourin Med 1997; 73:105-9.
25. Bodsworth NJ, Crooks RJ, Borelli S, Vejlsgaard G, Paavonen J, Worm AM, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. Genitourin Med 1997;73:110-6.
26. Lawrence AG, Bell AR, and the International Valaciclovir HSV Study Group. Valaciclovir for prevention of recurrent herpes simplex virus infection in HIV-infected individuals - a double-blind, controlled trial (abstract). In: Programs and Abstract of the 8th European Congress of Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland, May 25-28, 1997.
27. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988;6:1562-8.
28. Hallas J. Drug-related hospital admissions: the role of definitions and intensity of data collection and the possibility of prevention. J Int Med 1990;228:83-9.
29. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999;340:1462-70.
30. Egan J, Sheikh S, Woodcock A. Valacyclovir reduces the incidence of cytomegalovirus infection in heart transplant patients (abstract 151). Presented at: 9th Congress of the European Society for Organ Transplantation, Oslo, Norway, June 19 -24, 1999.
31. Ljungman P. Efficacy and safety of valacyclovir as a prophylaxis against CMV infection and disease in BMT recipients (abstract). J Clin Virol 1999;12:G6-02.